p: +1 608-716-7539

Voximetry strengthens image processing capabilities

Voximetry announces another strategic product development investment with the hiring of Dr. Chuck Stearns.

Dr. Stearns has over 30 years of experience in PET/CT scanner design, data processing and image reconstruction.

“Chuck’s deep domain knowledge in nuclear medicine imaging technology will solidify Voximetry’s ability to focus on image data inputs to Torch™, our advanced dosimetry software application for Radiopharmaceutical Therapy,” said Sue Wallace, CEO of Voximetry.

Dr. Stearns has a self-proclaimed passion for developing radioisotope imaging technology, bringing that technology to the clinic through commercial products, and helping practitioners understand that technology to incorporate it into their practice. He earned a Bachelor of Science in Biomedical Engineering from Case Western Reserve University, and a Master of Science in Electrical Engineering and Doctorate in Medical Engineering from MIT. For over 30 years Dr. Stearns worked at GE Healthcare in a number of engineering and advanced science positions focused on PET and PET/CT, including serving as Chief Engineer for PET/CT.

Dr. Stearns is a well-published scientist and frequent presenter at technical conferences. He holds 40 U.S. patents and has been recognized as a Fellow of the IEEE. In addition to his scientific interests, he is certified as a Six Sigma Black Belt, a complex business methodology to improve business performance.

Voximetry’s Chief Technology Officer & Co-founder, Paul Wickre, stated, “With the addition of Chuck to the team we can accelerate our work on GPU-accelerated SPECT/CT reconstruction as well as more advanced segmentation capabilities. I couldn’t be more pleased to add this proven leader to our team.”

About Voximetry: Voximetry is a Healthtech software company commercializing complex algorithms on high-speed Graphics Processing Units (GPUs). Currently focused on radiation transport science, Voximetry is advancing patient-specific treatment planning in late-stage cancer patients.

*510(k) pending. Torch™ is under FDA review and is NOT Available for Sale or Clinical Use